Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on March 13, 2024, regarding corporate governance changes effective upon the filing of the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Election: Anne Phillips was elected as a director, effective March 13, 2024. She was appointed Chair of the Compensation Committee and a member of the Audit Committee.
- Director Resignations: John Fry and Howard Weiner resigned from their director roles effective upon the filing of the 2023 Annual Report, consistent with a prior report filed on February 23, 2024.
- Independence: Ms. Phillips is classified as an "independent" director under Nasdaq rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No risks, contingencies, or unusual items were disclosed in this specific report. Ms. Phillips entered into the Company's standard form of indemnification agreement, and no reportable transactions under Item 404(a) of Regulation S-K exist between her and the Company.
Investor Verification Checklist
- Verify the composition of the Board of Directors following the resignation of John Fry and Howard Weiner.
- Confirm Anne Phillips' qualifications and independence status as disclosed in the 2023 Annual Report.
- Review the standard form of indemnification agreement referenced in the filing.
- Check for any subsequent filings regarding the Company's financial status, as this 8-K contains no financial data.